Management of pemphigus in pediatric patients

Area of Science:

• Pediatric Dermatology
• Autoimmune Blistering Diseases

Background:

• Pemphigus management in pediatric patients is categorized into childhood (≤12 years) and juvenile (13-18 years) pemphigus.
• Mucocutaneous involvement, including oral, nasal, ocular, anal, and genital regions, is prevalent in both pediatric groups.
• Autoantibodies are detectable in most patients' sera.

Purpose of the Study:

• To review the management, treatment outcomes, and prognosis of pemphigus in pediatric patients.
• To highlight the challenges associated with corticosteroid therapy and explore alternative treatment options.

Main Methods:

• Review of literature on childhood and juvenile pemphigus.
• Analysis of treatment modalities, including corticosteroids, immunosuppressive agents, Dapsone, sulphapyridine, Intravenous immunoglobulin (IVIg), and Rituximab.
• Evaluation of treatment duration, side effects, and long-term prognosis.

Main Results:

• Oral corticosteroids are the primary treatment, but 50-67% of patients experience systemic side effects, notably growth retardation (50%).
• Immunosuppressive agents are utilized for steroid-sparing effects; Dapsone and sulphapyridine are underutilized.
• Treatment duration is typically 2-3 years with a generally good prognosis. Intravenous immunoglobulin (IVIg) and Rituximab show promise for specific cases.

Conclusions:

• Pemphigus in pediatric patients has a good prognosis, with no evidence of adult continuation or recurrence after remission.
• Early diagnosis through biopsy and direct immunofluorescence is crucial for pediatric patients presenting with blisters or erosions.
• Careful monitoring for side effects and consideration of steroid-sparing agents are essential in managing pediatric pemphigus.